Hong Kong's First 2022 Biotech IPO Debuts

Plus Other Broad Funding Across Modalities

One IPO on the Hong Kong Stock Exchange and seven venture capital or private equity deals raised a combined $329m in China in February.

fund raising
VC/PE investors continued injecting capitals into Chinese biotechs, and small molecule developers obtained the largest share. • Source: Alamy

More from China

More from Focus On Asia